Becker's Healthcare September 26, 2024
Alexandra Murphy

The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating schizophrenia in decades, Medscape reported Sept. 20.

Here are five things to know:

  1. KarXT is a coformulation of xanomeline and trospium chloride, designed to selectively activate muscarinic receptors in the brain, unlike traditional antipsychotics that primarily target dopamine receptors.
  2. The safety and effectiveness of the drug was assessed in phase 3 trials, which showed KarXT had a 9.6 point reduction in positive and negative syndrome scale scores compared to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
1st gene therapy delivered directly into brain approved
How HHS, FDA, and CDC Can Influence U.S. Vaccine Policy
Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval
New FDA rules for TV drug ads to take effect: 4 things to know
Artificial heart saves 4th patient

Share This Article